Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Shanghai Pudong Hospital
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota